Abiopharma

Proof-of-Concept Results Show Jaguar Healths Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

FDA approve DANICOPAN

FDA approve MYCOPHENOLIC SODIUM

New Form 8-K - One World Products, Inc. Filed: 2025-06-30 AccNo: 0001641172-25-017060 Size: 256 KB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Microbot Medical® Added to the RussellMicrocap® Index

New Form 8-K - IN8BIO, INC. Filed: 2025-06-30 AccNo: 0001193125-25-152037 Size: 139 KB Item 8.01: Other Events

New Form 8-K - Microbot Medical Inc. Filed: 2025-06-30 AccNo: 0001641172-25-017053 Size: 232 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - ONCOLYTICS BIOTECH INC Filed: 2025-06-30 AccNo: 0001129928-25-000041 Size: 34 KB

New Form S-1/A - Cellectar Biosciences, Inc. Filed: 2025-06-30 AccNo: 0001104659-25-063849 Size: 1 MB

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

FDA approve EMAPALUMAB-LZSG

New Form 424B5 - CorMedix Inc. Filed: 2025-06-30 AccNo: 0001213900-25-059256 Size: 476 KB

New Form 8-K - 23andMe Holding Co. Filed: 2025-06-30 AccNo: 0001193125-25-152020 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Summit Plc - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

New Form 8-K - Tyra Biosciences, Inc. Filed: 2025-06-30 AccNo: 0001193125-25-152016 Size: 141 KB Item 8.01: Other Events